Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges

被引：50
作者：
Bakht M.K. [1 ,2 ,3 ]
Oh S.W. [1 ,2 ]
Youn H. [1 ,2 ]
Cheon G.J. [1 ,2 ]
Kwak C. [4 ]
Kang K.W. [1 ,2 ]
机构：
[1] Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul
[2] Laboratory of Molecular Imaging and Therapy, Cancer Research Institute, Seoul National University College of Medicine, Seoul
[3] Department of Biological Sciences, University of Windsor, Windsor, N9B 3P4, ON
[4] Department of Urology, Seoul National University College of Medicine, Seoul
来源：
Nuclear Medicine and Molecular Imaging | 2017年 / 51卷 / 3期
关键词：
Antiandrogens; Molecular imaging; Positron emission tomography; Prostate cancer; Prostate-specific membrane antigen;
D O I：
10.1007/s13139-016-0439-4
中图分类号：
学科分类号：
摘要：
Prostate-specific membrane antigen (PSMA) is an attractive target for both diagnosis and therapy because of its high expression in the vast majority of prostate cancers. Development of small molecules for targeting PSMA is important for molecular imaging and radionuclide therapy of prostate cancer. Recent evidence implies that androgen-deprivation therapy increase PSMA-ligand uptake in some cases. The reported upregulations in PSMA-ligand uptake after exposure to second-generation antiandrogens such as enzalutamide and abiraterone might disturb PSMA-targeted imaging for staging and response monitoring of patients undergoing treatment with antiandrogen-based drugs. On the other hand, second-generation antiandrogens are emerging as potential endoradio-/chemosensitizers. Therefore, the enhancement of the therapeutic efficiency of PSMA-targeted theranostic methods can be listed as a new capability of antiandrogens. In this manuscript, we will present what is currently known about the mechanism of increasing PSMA uptake following exposure to antiandrogens. In addition, we will discuss whether these above-mentioned antiandrogens could play the role of endoradio-/chemosensitizers in combination with the well-established PSMA-targeted methods for pre-targeting of prostate cancer. © 2016, Korean Society of Nuclear Medicine.
引用
收藏
页码：202 / 211
页数：9
相关论文
共 67 条
[61]  
Chatalic K.S., Heskamp S., Konijnenberg M., Molkenboer-Kuenen J.M., Franssen G.M., Clahsen-van Groningen M.C., Et al., Towards personalized treatment of prostate cancer: PSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent, Theranostics, 6, pp. 849-861, (2016)
[62]  
Lee S.J., Zhang Y., Lee S.D., Jung C., Li X., Kim H.S., Et al., Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer, Mol Ther, 10, pp. 1051-1058, (2004)
[63]  
Cheng W.S., Kraaij R., Nilsson B., van der Weel L., de Ridder C.M., Totterman T.H., Et al., A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer, Mol Ther, 10, pp. 355-364, (2004)
[64]  
Ikegami S., Tadakuma T., Suzuki S., Yoshimura I., Asano T., Hayakawa M., Development of gene therapy using prostate‐specific membrane antigen promoter/enhancer with Cre recombinase/LoxP system for prostate cancer cells under androgen ablation condition, Jap J Cancer Res, 93, pp. 1154-1163, (2002)
[65]  
Zhao W., Xu Y., Kong D., Liu R., Zhang Z., Jin C., Et al., Tissue-selective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer, Urol Oncol, 27, pp. 539-566, (2009)
[66]  
Zhao F.J., Zhang S., Yu Z.M., Xia S.J., Li H., Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosylltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer, Prostate Cancer Prostatic Dis, 12, pp. 166-171, (2009)
[67]  
Zeng H., Wei Q., Huang R., Chen N., Dong Q., Yang Y., Et al., Recombinant adenovirus mediated prostate‐specific enzyme pro‐drug gene therapy regulated by prostate‐specific membrane antigen (PSMA) enhancer/promoter, J Androl, 28, pp. 827-835, (2007)
1234567